Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer
Conditions:   Locally Advanced Pancreatic Adenocarcinoma;   Locally Advanced Unresectable Pancreatic Adenocarcinoma;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Unresectable Pancreatic Adenocarcinoma
Interventions:   Radiation: Hypofractionated Radiation Therapy;   Drug: Peposertib;   Other: Placebo Administration
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments